Synpopsis: Shares of this company surged 11% in today’s session, as investor Mukul Agrawal acquired a 3.4% stake in March 2026, signaling confidence in its growth and future prospects.
The shares of this Indian healthcare company specialising in fertility treatments such as IVF (in-vitro fertilization), ICSI, and other reproductive services are in the spotlight after it rose by 11% in today’s session following ace investor Mukul Agrawal’s pick up of a stake.
With a market capitalisation of Rs. 823 cr, the shares of Gaudium IVF and Women Health Ltd were trading at Rs. 113.07, surging 11% in today’s market session, making a high of Rs. 114.95, up from its previous close of Rs. 103.38 per share. The stock was listed on NSE and BSE on February 27, and has since gained 40%.
News
During the March 2026 quarter, noted Indian Ace investor Mukul Agrawal made a significant investment in Gaudium IVF and Women Health Ltd by acquiring a 3.4% equity stake in the company.
This investment translates to approximately 25 lakh (2.5 million) shares, indicating a meaningful level of confidence in the company’s growth prospects. Such a stake suggests that Agrawal sees strong potential in the expanding fertility and reproductive healthcare sector in India, and his entry is often viewed by market participants as a positive signal regarding the company’s future performance and scalability.
About the company
Gaudium IVF and Women Health Ltd is an Indian healthcare company specialising in fertility treatments such as IVF (in-vitro fertilization), ICSI, and other reproductive services. The organization operates a network of advanced fertility clinics across multiple states in India, focusing on personalized, patient-centric care and modern reproductive technologies. The company serves patients from various countries, including Canada, the United Kingdom, the United States, Kenya, South Africa, and Oman.
Sales of the company fell from Rs. 31.73 cr in Q2FY26 to Rs. 24.51 cr in Q3FY26. Operating profit also decreased to Rs. 6.56 cr from Rs. 13.77 cr. Net profit fell significantly from Rs. 9.38 cr to Rs. 3.63 cr over the same period.
The company demonstrates strong financial performance, with a high ROCE of 48.6% and ROE of 52.2%, indicating efficient use of capital and strong returns for shareholders. Its debt-to-equity ratio of 0.41 suggests a relatively low reliance on debt. Over the past three years, it has achieved solid growth, with compounded profit growth of 29% and sales growth of 25%, reflecting consistent business expansion.
It has several competitive strengths, including a strong patient-centric approach and an expert medical team. The company leverages advanced technologies such as next-generation INTEGRA Ti labs for ICSI and highly technical USG-guided procedures. Its presence in key urban hubs like Mumbai, Bangalore, Delhi NCR, and Patna strengthens accessibility, while its asset-light business model supports scalability and efficient operations.
The company planned to utilise its IPO proceeds primarily to support growth and financial stability. Around Rs. 50 crore will be used to set up new IVF centers, Rs. 20 crore will go toward repaying or pre-paying existing loans, and the remaining Rs. 12.28 crore will be allocated for general corporate purposes, taking the total to Rs. 82.28 crore.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
